Soluble Fas molecule in the serum of patients with systemic lupus erythematosus

Journal of Clinical Immunology

Volumn 16, Issue 5, 1996, Pages 261-265

  Tokano, Yoshiaki ^a   Miyake, Sachiko ^a   Kayagaki, Nobuhiko ^a   Nozawa, Kazuhisa ^a   Morimoto, Shinji ^a   Azuma, Miyuki ^a   Yagita, Hideo ^a   Takasaki, Yoshinari ^a   Okumura, K ^a   Hashimoto, Hiroshi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

lymphopenia; soluble CD4; soluble Fas; systemic lupus erythematosus

Indexed keywords

CD23 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; PREDNISOLONE; STEROID;

APOPTOSIS; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LYMPHOCYTOPENIA; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD4; ANTIGENS, CD8; ANTIGENS, CD95; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPENIA; PREDNISOLONE; RECEPTORS, IGE;

EID: 10144241017     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01541390     Document Type: Article

References (24)

1. Russell JH, White CL, Loh DY, Meleedy-Rey P: Receptor-stimulated death pathway is opened by antigen in mature T cells. Proc Natl Acad Sci USA 88:2151-2155, 1991
2. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233-243, 1991
3. Watanabe-Fukunaga R, Brannan CI, Itoh, N, Yonehara S, Copeland NG, Jenkins NA, Nagata S: The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 148:1274-1279, 1992
4. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J. Trauth BC, Ponsting H: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J Biol Chem 267:10709-10715, 1992
5. Itoh N, Nagata S: A novel protein domain required for apoptosis. J Biol Chem 268:10932-10937, 1993
6. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH: Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181:71-77, 1995
7. Ju S, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444-448, 1995
8. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins A, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317, 1992
9. Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152:3685-3692, 1994
10. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecle. Science 263:1759-1762, 1994
11. Yu DTY, Winchester RJ, Fu SM, Gibfsky A, Ko HS, Kunkel HG: Peripheral blood Ia-positive T cells. Increases in certain diseases and after immunization. J Exp Med 151:91-100, 1980
12. Tokano Y, Murashima A, Takasaki Y, Hashimoto H, Okumura K, Hirose S: Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Ann Rheum Dis 48:803-809, 1989
13. Tokano Y, Hishikawa T, Hirose T, Sekigawa I, Hashimoto H, Okumura K, Hirose S: HLA-DP-positive T cells in patients with systemic lupus erythematosus. Autoimmunity 5:179-183, 1990
14. Murashima A, Takasaki Y, Ohgaki M, Hashimoto H, Shirai T, Hirose S: Activated peripheral blood mononuclear cells detected by murine monoclonal antibodies to proliferating cell nuclear antigen in active lupus patients. J Clin Immunol 10:28-37, 1990
15. Sawada S, Hashimoto H, Iijima S, Tokano Y, Takei M, Shida M, Obara T: Immunologic significance of increased soluble CD8/CD4 molecules in patients with active systemic lupus erythematosus. J Clin Lab Anal 7:141-146, 1993
16. Yoshikawa T, Nanba T, Kato H, Hori K, Inamoto T, Kumagai S, Yodoi J: Soluble FcεRII/CD23 in patients with autoimmune diseases and Epstein-Barr virus-related disorders: Analysis by ELISA for soluble FcεRII/CD23. Immunomethods 4:65-71, 1994
17. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arth Rheum 25:1271-1277, 1982
18. Liang WH, Socher SA, Larson MG, Schur PH: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arth Rheum 32:1107-1118, 1989
19. Cifone MG, Maria RD, Roncaioli P, Rippo MR, Azuma M, Lanier LL, Santoni A, Testi R: Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J Exp Med 177:1547-1552, 1994
20. Winfield JB, Winchester RJ, Kunkel HG: Association of cold-reactive antilympocyte antibodies with lymphopenia in systemic lupus erythematosus. Atrh Rheum 18:587-594, 1975
21. Amasaki Y, Kobayashi S, Takeda T, Ogura N, Jodo S, Nakabayashi T, Tsutsumi A, Fujisaku A, Koike T: Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): A possible mechanism for lymphopenia. Clin Exp Immunol 99:245-250, 1995
22. Knipping E, Krammer PH, Onel KB, Lehman TJA, Mysler E, Elkon KB: Levels of soluble Fas/Apo-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arth Rheum 38:1735-1737, 1995
23. Goel N, Ulrich DT, Clair WS, Fleming JA, Lynch DH, Seldin MF: Lack of correlation between serum soluble Fas/Apo-1 levels and autoimmune disease. Arth Rheum 38:1738-1743, 1995
24. + T cells responding to a bacterial superantigen. J Immunol 154:4302-4308, 1995